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ABSTRACT
Analysis of the Cytopathogenic Effect of Different HIV-1 Vpr Isoforms
on Primary Human CD4+ T Cells and a Model Cell Line
Jonatan Josue Fierro Nieves
Department of Microbiology and Molecular Biology, BYU
Master of Science
Human Immunodeficiency Virus (HIV) is the causal agent of acquired immunodeficiency
syndrome (AIDS), a disease characterized by the depletion of CD4+ T cells which impairs immune
response. Analysis of HIV-1 infected patients has identified two distinctive phenotypes that differ
in length of time towards the development of AIDS, Rapid Progressor (RP) and Long-Term NonProgressor (LTNP) patients. The cause of the differences between these two groups is a process
that is still under investigation. Hints about a possible cause have been attributed to the discovery
of mutations in the viral protein R (Vpr) that have been associated with these phenotypes:
mutations producing the isoforms R36W to RP patients and R77Q to LTNP patients. It has been
suggested that these mutations play an important role in the depletion of CD4+ T cells, however
more studies are needed to clarify and support this idea. This study examines the effect of the two
isoforms in the infection of human primary CD4+ T cells and a model cell line, using the viral
strain HIV-1 JR-CSF and derived strains to which the aforementioned mutations have been
induced. Our results show that after infection, isoform R77Q has the capacity to significantly
induce more apoptosis (identified by Annexin V staining) than Vpr wild type (WT) and the viral
strain expressing the isoform R36W. Moreover, R36W significantly induces more cell death by
necrosis than R77Q. Notably, the differences found in the way these isoforms of Vpr induce
necrosis and apoptosis support the idea of the correlation between strains harboring these
mutations and the phenotypes of RP and LTNP patients.
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INTRODUCTION
Section I - The Disease

1.1 An infectious agent
Human Immunodeficiency Virus (HIV), as the name states, is a virus capable of infecting
humans that can cause cellular immunodeficiency. When the body is infected with HIV, it
gradually loses its capacity to eliminate infections, and many pathogens that were once commonly
eliminated by the immune system, are now allowed to thrive. The aggregate of symptoms derived
from these opportunistic infections and the loss of the body’s cellular immunity are termed
acquired immunodeficiency syndrome (AIDS). This syndrome is the final stage of HIV infection
that, when untreated, commonly leads to the death of the infected person.
It is estimated that a person infected with HIV that is not receiving any kind of treatment
has an average life expectancy of 11 years [1]. Several factors contribute to the time it takes to
develop AIDS, including age, lifestyle, general health, incidence of other diseases, and the strain
of the virus [2]. It is important to mention that at the time of this thesis, there are several treatments
available that significantly increase the life expectancy of an HIV-infected patient.
There are two types of HIV, type 1 (HIV-1) and type 2 (HIV-2), and both can cause AIDS.
However, despite having the same name, the two viruses are very different, and even have different
origins. They are the result of two independent zoonotic transmissions of Simian
Immunodeficiency Viruses (SIVs) to humans that possibly became infected during manipulation
or consumption of hunted meat from Non-human Primates (NHPs). It is well known that NHPs
are reservoirs of many different SIVs, and different species of NHPs have persistent SIV infections
[3]. Based on phylogenetical analysis, it was determined that HIV-1 originated in Central African
chimpanzees, where it was transmitted to humans, and HIV-2 has its origins in West African sooty
1

mangabeys [4, 5]. The exact point in time where these infections happened is difficult to determine
but based on genomic analysis of HIV-1, it has been estimated that an early established human
infection could have happened around the 1920s [6]. The main difference between the two viruses
is their pathogenicity. HIV-2 infection is not as easily transmissible as HIV-1, and is mainly
distributed in West Africa, where about two million people are infected, predominantly in
countries like Senegal, Ivory Coast, and Sierra Leone [7]. HIV-2 infection produces low levels of
viral loads that in many cases are undetectable, which diminishes the immune response, provoking
a longer latent period and a delay in the development of AIDS compared to HIV-1 [8]. On the
other hand, HIV-1 long ago reached the status of pandemic, as the infection is distributed
worldwide, and affects, as of 2020, more than 37 million people, of which more than half a million
die annually [9]. The serious effects that HIV-1 has on the current global population makes it an
urgently important target for research and treatment development.
One of the most significant features of HIV-1 is its capacity to infect and replicate inside
CD4+ T lymphocytes, provoking their depletion [10]. This cell type plays a critical role in human
immunity against most types of pathogens. Lack of CD4+ T cells is the main cause of the
immunodeficiency associated with this virus; when enough of these cells are depleted, the body is
incapable of eliminating opportunistic diseases, which are ultimately the most prevalent cause of
death of an AIDS patient [11].

1.2 Epidemiology
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As mentioned before, HIV infection was established in humans sometime in the early 20th
century, and not much is known about the individuals infected with HIV at the time of the
emergence of the disease, although some clinical studies have described patients with similar
symptoms to those presented in AIDS. In a retrospective study conducted by the University of
Chicago, where clinical cases from 1950 until January 1986 were analyzed, they found that at least
19 documented cases from different countries, including United States, West Germany, Belgium,
and Uganda, fulfill the Centers for Disease Control and Prevention (CDC) criteria for AIDS, and
nine cases were recognized as AIDS by both the CDC and the authors of the study [12].
In 1981, evidence of newly acquired cellular immunodeficiency was identified in blood
samples of patients diagnosed with Pneumocystis carinii pneumonia and mucosal candidiasis,
which showed that peripheral blood T-cell helper subpopulations were practically eliminated [13].
By 1983, the virus was isolated and identified as the causal agent of AIDS by Luc Montagnier and
Françoise Barré-Sinoussi at the Pasteur Institute in France [14]. In 1984, the United States
Department of Health and Human Services announced at a press conference that Robert Gallo had
determined that a retrovirus was the causal agent of AIDS [15]. This new virus was initially named
Lymphadenopathy Associated Virus (LAV) by Luc Montagnier, and Human T-lymphotropic
Virus type III (HTLV-III) by Roberto Gallo [15, 16], but it was not until a couple of years later, in
1986, that it was commonly agreed to name the new virus Human Immunodeficiency Virus (HIV).
The 2015 Global Burden of Disease Study estimates that the incidence of HIV infection
around the world peaked in 1997 at 3.3 million new infections. This global incidence fell rapidly
from 1997 to 2005, to about 2.6 million new infections per year [17] (Figure 1).
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Figure 1. Timeline of HIV infection and deaths from 1990 to 2019. Around 1997 new HIV cases worldwide
reached the highest point of infection in the history of this pandemic with about 3.3 new million cases.
Source: Max Roser and Hannah Ritchie (2018) - "HIV / AIDS". Published online at OurWorldInData.org.

To better understand the current impact of HIV on the human population, it is necessary to
know that as of 2020, about 79.3 million people have become infected with HIV since the start of
the epidemic in the early 1980s, of which approximately 36.3 million people have died from AIDSrelated illnesses. In 2020 only, about 37.7 million people were living with HIV globally, of which
680,000 people died from AIDS-related illnesses, and an estimated of 1.5 million were newly
infected [18]. Notwithstanding the millions of people infected with HIV, there is not equity in the
worldwide distribution of cases; the number of people infected with HIV/AIDS is not proportional
to the size population or location of the country, and among all countries, those most affected are
located in sub-Saharan Africa. In Eswatini, approximately 26.8% (200,000 cases) of adults aged
15-49 are living with HIV/AIDS, followed by Lesotho with 21.1% (340,000 cases), Botswana with
19.9% (380,00 cases), and South Africa with 17.3% (7,500,000 cases) [19] (Figure 2).

4

Figure 2. Distribution of people in the world living with HIV in 2019. Source: Max Roser and Hannah Ritchie
(2018) - "HIV / AIDS". Published online at OurWorldInData.org.

1.3 Transmission
HIV is transmitted through infected bodily fluids (blood, semen, breast milk, etc.) that
come in contact with mucosal surfaces or damaged tissues, or when the virus is directly injected
into the bloodstream. The risk of HIV infection varies broadly depending on the type of exposure,
sexual preference, gender, age, and other factors. In 2018, out of the 37,968 new HIV diagnoses
in the United States and dependent areas, men accounted for 30,691 (81%), and 26,394 (~86%) of
these cases were attributed to gay, bisexual, and other men who have sex with men [20]. The most
common form of transmission of the virus is through unprotected sexual intercourse. Several
factors increase the capacity of a person to infect another person during sexual relations, the two
most important being the presence of high levels of virus in plasma and the presence of other
sexually transmitted infections [21, 22].
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Another important transmission route of HIV is mother-to-child transmission. If a mother
is infected with HIV and is not under treatment, the approximate rate of infection of the newborn
is between 15% to 25%, and the numbers almost double (35% to 40%) if the baby is being
breastfed [23]. Analysis of viral transmission during gestation is possible, and it has been
demonstrated that a fetus can be infected by the mother as early as week 12 of gestation, however,
the vast majority of vertical infections have been documented in the final trimester of gestation,
and during a short period of time before or during delivery [24]. Since the virus can be transmitted
through breast milk, when a mother is infected with HIV it is recommended to not breastfeed. In
the United States, the CDC and the American Academy of Pediatrics (AAP) recommend to
completely avoid breastfeeding, and to use alternatives like infant formula or pasteurized donor
human milk [25]. In places where access to these alternatives and treatment is limited, such as in
developing countries, the World Health Organization (WHO) recommends that mothers infected
with HIV should exclusively breastfeed for 6 months, after which period it is recommended to add
complementary food, and to breastfeed until 12 months of age [26].
Transmission of HIV is more than just the virus crossing membranes, reaching, and
infecting cells. Transmission also includes risk factors and populations at risk. For the purposes of
this section, only one of the most important risk factors will be described, which also designates a
population at risk: people with substance abuse disorders. The abuse of drugs like alcohol,
marijuana, and other substances have been identified as an important risk factor concerning HIV
infection. The correlation is based on the loss of clear judgment when a person has abused a
substance, which can lead to risky sexual behaviors like having sexual intercourse without a
condom or having multiple partners. Regarding the use of drugs, an important risk factor is sharing
used needles or equipment for drug injection. If a person is infected with HIV, sharing a used
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needle allows the percutaneous inoculation of the virus in a non-infected person. People who use
injected drugs account for about 10% of all the HIV cases in the United States [20].

1.4 Diagnosis
There are two approaches to diagnosing HIV infection, each based on different principles:
one is based on the identification of antibodies produced by the body against the virus, and the
other is based on the detection of the viral particle in the blood.
An initial test for the diagnosis of HIV is the enzyme-linked immunoassay (ELISA assay),
which identifies antibodies produced by the body’s immune response against antigens of the virus.
When a patient has tested positive through this initial test, they are considered seropositive, and a
confirmation test is required. Testing a patient for the production of antibodies is usually performed
4 to 5 weeks after exposure, and despite variations in immune response, this timeframe is an
average time where an infection can be serologically determined [27].
To confirm that a patient is infected with HIV, an immunoblot test is performed.
Confirmation is necessary to discard false-positive results for the presence anti-HIV antibodies
because it is possible to test positive to the initial test when immune complexes are present in the
blood. Common causes for the presence of these complexes are infections with other pathogens,
vaccination, and autoimmune diseases. In the immunoblot test, antibodies are isolated from the
blood and are used to identify viral proteins in a sample. The test looks for antibodies against
proteins of the viral envelope (gp41 and gp120/gp160), proteins from the core of the virus (p17,
p24 and p55), and some accessory proteins (p31, p55 and p66). When the immunoblot test results
positive, the infection with HIV is considered confirmed [28].
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Detection of viral particles: to detect the virus, a modified version of the technique ELISA,
called sandwich ELISA, is performed. This technique usually uses antibodies against the viral
protein p24, which can detect this protein in the blood with a sensitivity of 10 pg/ml, which
corresponds to about 100,000 viral particles per ml of blood [27]. If the viral protein p24 is
identified in a sample, this positive result also needs to be confirmed. Confirmation of a positive
sample can be done by blocking-neutralization tests, or by a Nucleic Acid Amplification
Technology (NAT) test, which is the standard test for confirmation in USA. With a NAT test, it is
possible to detect the viral genome in plasma, extract RNA, and amplify specific viral sequences,
and depending on the targeted sequences, this test allows the detection of the equivalent of 40 to
100 genomes per ml of plasma [29].

1.5 AIDS
The natural course of infection with HIV leads to the development of AIDS, which is, as
mentioned before, the final and usually fatal stage of the disease (Figure 3). There are three main
stages of the progression of HIV, as follows:
Stage 1 - acute infection: in the timeline of the progression of the disease, this stage
commonly extends from week 2 to week 10 after infection. It is characterized by rapid
multiplication of the virus, and high levels of circulating viruses can be detected during this period
(viral load 105-109 genome copies/ml) [30]. The viral load leads to an important drop in the number
of circulating CD4+ cells in a short period of time, however the count of CD4+ cells is usually over
500 per µl of plasma [31] . The clinical symptoms of this stage include fever, headache, and rash,
and comparable to a common flu, patients in this stage are very contagious [32].
Stage 2 - chronic infection: this stage is also referred to as clinical latency. In this stage,
the level of circulating CD4+ cells returns to a near-normal level, and levels of circulating viruses
8

drops dramatically (below 102 genome copies/ml to undetectable levels) [31, 33]. The virus is still
infecting and multiplying, but at very low levels, so patients in this stage may not have any clinical
symptoms. Unlike stage 1, this stage lasts a very long period of time, determined manly by the
response of the immune system to the viral infection. The duration of this stage normally includes
the next 7 to 10 years, but it can be considerably shorter if the patient is more susceptible to the
virus. It is possible to identify the end of stage 2, because levels of circulating viruses rise and
levels of circulating CD4+ cells drop again [32].
Stage 3 - AIDS: this is the last stage of HIV infection, which occurs at an average time of
11 years after infection [1]. Patients are diagnosed with AIDS when the count of CD4+ cells falls
below 200 cells/µl of plasma, while the normal count in a healthy person ranges between 500 to
1500 cells/µl of plasma [31, 34]. In this stage, the body presents a remarkable immunodeficiency
and is incapable of mounting a functional immune response, opportunistic infections and
neoplasms are developed in this stage. Frequent opportunistic infections include Cryptosporidium,
Isospora, Histoplasmosis, Tuberculosis, Herpes, Toxoplasmosis, Cryptococcal meningitis,
Candidiasis, etc. [35].
Clinically, AIDS is characterized by periods of illness followed by periods of good health,
and with the progression of the disease and the immunodeficiency, the periods of illness become
longer-lasting [36]. In time, the patient will lose the capacity to eliminate these opportunistic
infections and will succumb to them.
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Figure 3. Disease progression of HIV infection. In the acute phase HIV induces a normal primary immune
response. In clinical latency HIV remains latent and the immune system is not capable of mounting an
efficient response to eliminate the virus. During AIDS many opportunistic diseases appear, the immune
response is impaired and secondary infections are the cause of death. Source HIV-timecourse, CC0 1.0
Universal (CC0 1.0) Public Domain Dedication. No Copyright

1.6 Prevention methods
In many instances, social factors play an important role in the infection of HIV, because it
is human behavior that leads to exposure. Some exposures entail a high risk of transmission, two
examples being sharing needles when using injectable drugs, and having sex with multiple partners
without a condom [37]. Notably, the most effective prevention method for sexually transmitted
infections (STIs) including HIV, is the correct use of the male condom. Regarding HIV, it is
estimated that the consistent and correct use of latex condoms reduces the risk of infection with
HIV by about 80% for heterosexual transmissions and about 70% for male‑to‑male sexual
transmissions [38, 39]. Every exposure has a degree of risk, which is important to acknowledge;
Table 1 shows the risk of transmission per 10,000 exposures of different kinds.
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Table 1. Estimated Per-Act Probability of Acquiring HIV from an Infected Source, by Exposure Act*
Type of Exposure

Risk per 10,000 Exposures

Parenteral
Blood Transfusion

9,250

Needle-Sharing During Injection Drug Use

63

Percutaneous (Needle-Stick)

23

Sexual
Receptive Anal Intercourse

138

Insertive Anal Intercourse

11

Receptive Penile-Vaginal Intercourse

8

Insertive Penile-Vaginal Intercourse

4

Receptive Oral Intercourse

Low

Insertive Oral Intercourse

Low

Other^
Biting

Negligible

Spitting

Negligible

Throwing Body Fluids (Including Semen or Saliva)

Negligible

Sharing Sex Toys

Negligible

* Factors that may increase the risk of HIV transmission include the presence of other sexually transmitted
infections, acute and late-stage HIV infection, and high viral load. Factors that may decrease the risk include
condom use, male circumcision, antiretroviral treatment, and pre-exposure prophylaxis. None of these
factors are accounted for in the estimates presented in the table. ^ HIV transmission through these exposure
routes is technically possible but unlikely and not well documented. Source Division of HIV Prevention,
National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
https://www.cdc.gov/hiv/pdf/risk/estimates/cdc-hiv-risk-behaviors.pdf
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Prevention does not mean only avoiding becoming infected with HIV, it also includes
preventing transmitting it to healthy individuals. This could be achieved by prevention methods
like the use of prophylactic drugs, reducing the number of sexual partners, sexual abstinence,
getting tested and treated for STIs, etc. A slightly different prevention method, to which only men
have access, is medical circumcision. It has been demonstrated that this procedure has the capacity
to reduce HIV acquisition by those who have it done by 50-60% when compared with
uncircumcised men [40-42]. Circumcision can not only to reduce the risk of infection with HIV
but also other STIs [43]. The mechanisms by which circumcision confers protection against STDs
is not well understood, but it is proposed that the microenvironment created by the foreskin
facilitates HIV infection through epithelium disruption and recruitment/activation of neutrophils
and susceptible CD4 T cells [44].
Infection with HIV in many cases can be successfully prevented by one or a combination
of the aforementioned methods, but not cured, which means that the almost 300-year-old advice
Benjamin Franklin gave is still applicable: “an ounce of prevention is worth a pound of cure.” In
the last few decades, the cornerstone in prevention and treatment of HIV has been the use of a
combination of drugs that block different stages of HIV replication, known as antiretroviral
therapy (ART). Patients taking anti-HIV drugs usually present a general state of good health, as
treatment usually can suppress replication of the virus to undetectable levels, decreasing the risk
of transmission, improving immune function, and stopping the advancement of the disease to
subsequent stages in a matter of weeks [45].
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The development of ART has had an important impact on the global population since the first
antiretroviral drug was approved in 1987. In 2016 alone, about 1 million people died from a cause
related to HIV/AIDS, but more importantly, about 1.2 million deaths were prevented as a result of
ART. The significance of this is that without ART, the number of deaths related to HIV/AIDS
would have been more than double (Figure 4).

Figure 4. HIV/AIDS deaths adverted due to ART. Source Max Roser and Hannah Ritchie (2018) - "HIV / AIDS".
Published online at OurWorldInData.org.
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Section II - The Virus

2.1 Structure
The HIV-1 viral particle, or virion, is mostly spherical in shape, and as with most viruses,
is very small, even when compared to a human cell. The average size of an erythrocyte is 7 µm in
diameter, while the HIV-1 virion is on average 130 nm, meaning that the cell is about 54 times
larger than the virion [46]. Despite its small size, HIV is not simple; morphologically, it has four
elementary structures: an outer envelope, a matrix protein composed of the viral protein p17, an
inner capsid composed of about 2,500 copies of the viral protein p24, and the viral RNA genome
(combined with nucleocapsid proteins) which is located inside the capsid. Other proteins are
present inside the capsid, including the enzymes reverse transcriptase, integrase, and protease [46,
47] (Figure 5).

Figure 5. Schematic representation of HIV. By Thomas Splettstoesser (www.scistyle.com) Own work, CC BY-SA.

The envelope is a lipid bilayer (plasma membrane) that the virus takes from the host cell.
When the virus acquires its membrane, host proteins like the major histocompatibility complex
(MHC), lymphocyte function-associated antigen 1 (LFA-1), and a cell surface adhesion receptor
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(CD44) are also taken, and consequently, they are present on the surface of the virus [48-50].
Additionally, the envelope displays the viral glycoproteins gp41 and gp120, which together form
a structure called envelope glycoprotein complex, where a trimer of gp120 is non-covalently linked
to a trimer of gp41, which has a transmembrane domain [51].

2.2 Classification
HIV uses the enzyme reverse transcriptase (RT) in the process of replication of its RNA
genome, and for this reason it has been classified as part of the Retroviridae family. The RT is in
charge of converting the RNA genome of the virus to DNA. If we follow the flow of the central
dogma of molecular biology, which explains that the natural direction of genetic information in
living organisms moves from DNA to RNA, and that RNA is used to make functional products as
proteins, we acknowledge why HIV is considered to go against the common flow of genetic
expression, and the suffix retro is used to denote this characteristic in the name of the family.
Within the Retroviridae family, HIV belongs to the genus lentivirus, which includes
viruses that are associated with persistent infections in animals and humans. Lentiviruses have
been identified to infect non-human primates, horses, cattle, sheep, goats, and more. The genus
includes human immunodeficiency viruses HIV-1 and HIV-2, simian immunodeficiency viruses
(SIV), bovine immunodeficiency virus (BIV), feline immunodeficiency virus (FIV), among others
[52]. The suffix lenti from Latin means slow, which is a reference to the long incubation period of
the disease produced by these viruses. As previously mentioned, HIV is a zoonotic virus
transmitted to humans from non-human primates, however, the establishment of HIV as a human
disease is not the result of single event, as independent transmission of SIVs to humans generated
different HIV lineages of the virus. There are four lineages of HIV-1, denominated groups M, N,
O and P, and two lineages of HIV-2, denominated groups A and H.
15

The most important HIV group is group M, as viruses belonging to this group are the causal
agents of the AIDS global pandemic that affects millions. Group O, which is mainly located in
West-Central Africa, is responsible for thousands of cases in this area, and only a few cases of
HIV are derived from groups N and P, which have been found mainly in Cameroon [53-57].
Group M, in turn, is subdivided into nine subtypes (A, B, C, D, F, H, J, and K). These are
the result of the diversification of HIV after establishing in humans, and they are distributed in
different regions due to the place where they originated. It has been estimated that subtypes can
differ by approximately 30% of their genome sequence [58, 59]. Furthermore, there are many
circulating recombinant forms (CRFs) of HIV, the consequence of recombination between two or
more subtypes in a determined region [60, 61] (Figure 6). Globally, about 47% of HIV infections
are attributed to subtype C, 12% to subtype B, 10% to subtype A, 8% to circulating recombinant
form CRF02_AG, and 5% to CRF01_AE [62].

Figure 6. HIV-1 subtype prevalence in 2002. By Grcampbell - Based on Osmanov S, Pattou C, Walker N,
Schwardlander B, Esparza J; WHO-UNAIDS Network for HIV Isolation and Characterization. (2002) Estimated
global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic
Syndr. 29(2):184-90.
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2.3 Genome
HIV-1 has a diploid genome consisting of two identical copies of positive sense singlestranded RNA (+ssRNA), although the virus only uses one copy to generate a single DNA
provirus. The DNA genome consists of about 9,752 nucleotides and is flanked by long terminal
repeat (LTR) sequences at each end. HIV-1 has three major genes named gag, pol and env, that
code for structural proteins viral enzymes, and envelope proteins, respectively, and other genes
that code for accessory and regulatory proteins (Figure 7), with an total outcome of 16 viral
proteins presented in Table 2 [63].

Figure 7. Structure of the RNA genome of HIV-1. Source: By Thomas Splettstoesser (www.scistyle.com) - Own
work, CC BY-SA 3.0,

The gene gag codes for the polyprotein Pr55Gag, which is a precursor of four structural
proteins; after a proteolytic process, the resultant proteins are: Matrix protein (p17) that forms the
inner membrane layer, Capsid protein (p24) which gives shape to the capsid and virion,
Nucleoprotein (p7) that is involved in the formation of the nucleoprotein/RNA complex, and
Protein p6 that is involved in releasing the viral particle [64, 65].
The pol gene codes for the polyprotein Pr160GagPol, that also requires proteolytic
processing, and is the precursor of the following viral enzymes: Protease (p10), a proteolytic
enzyme whose main function is to cleave Pr55Gag and Pr160GagPol; Reverse transcriptase (p51),
the enzyme responsible for the transcription of HIV-1 RNA into DNA; RNase (p15), this enzyme
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degrades the RNA portion of the RNA/DNA duplex after the first strand of DNA is created; and
Integrase (p32) that leads the integration of DNA (provirus) into the host genome [64, 65].
The env gene codes for the protein PrGp160, which is the precursor of two glycoproteins
after cleavage: Surface glycoprotein gp120, the main protein for attachment of the virus to the host
cell; and transmembrane protein gp41, which is bonded to gp120 and facilitates the fusion of
membranes with the host cells [64, 65].
Other accessory and regulatory proteins include Nef, (p27) that enhances infectivity of
viral particles; Vif (p23), which is necessary for virus production in vivo; Vpr (p15), that facilitates
virus infectivity and affects the cell cycle; Vpu (p16), involved in intracellular trafficking; Tat
(p14), which works as an activator of transcription of viral genes; and Rev (p19), which regulates
the export of non-spliced and partially spliced viral mRNA. HIV-2 does not contain Vpu, but
instead produces Vpx (Viral protein x), which difference is partially responsible for the lower
infectivity of this virus [64-66]. Some proteins have been associated with many other functions.
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Table 2. HIV-1 Protein products.
Gene

gag

pol

env

Protein product

Class

Gag polyprotein Pr55Gag - Processed protein product:

Structural

Matrix protein (p17), Capsid protein (p24), Nucleoprotein (p7), and p6

Proteins

Pol polyprotein Pr160GagPol - Processed protein product:

Viral

Protease (p10), Reverse transcriptase (p51), RNase (p15), and Integrase (p32)

enzymes

PrGp160 polyprotein - Processed protein product: Surface glycoprotein

Envelope

(gp120) and Transmembrane protein (gp41)

proteins

nef

Negative regulating factor – Nef (p270)

vpr

Virus protein r - Vpr (p15)

Accessory
proteins

vif

Viral infectivity protein - Vif (p23)

vpu

Virus protein unique – Vpu (p16)

tat

Transactivator protein Tat (p14)

rev

RNA splicing regulator – Rev (p19)

*The size of the proteins (pX) or glycoproteins (gpX) is expressed in 1,000 Da.
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Regulatory
proteins

2.4 Replication cycle
Among the most important immune cells that are consistently infected by HIV-1 are CD4+
T cells and macrophage-linage cells, which commonly express CD4: the protein that the virus uses
as primary receptor. The CD4 protein normally functions as a co-receptor of the major
histocompatibility complex class II (MHCII) during T-cell recognition of a foreign antigen [67].
In addition to CD4, the virus requires at least one co-receptor to help it successfully and efficiently
bind and infect a human cell, and although several have been identified that can fulfill this role,
the two most important are CXCR4 and CCR5 [68, 69].
The virus initially attaches to the cell receptor (CD4) through the viral glycoprotein gp120.
When the virus is sexually transmitted, it commonly attaches to macrophages and dendritic cells
using the coreceptor CCR5. Viral strains that preferentially use this co-receptor are denominated
R5 tropic viruses, whereas strains that use the co-receptor CXCR4 are denominated X4 tropic
viruses. When the virus is directly exposed to blood cells (as when an infected person shares a
needle, or when infected blood enters broken skin), it can infect CD4+ T cells, and viruses that are
R5 tropic and X4 tropic can be transmitted. The replication cycle of HIV can be divided into six
main events: (1) binding and entry, (2) uncoating, (3) reverse transcription, (4) integration, (5)
protein synthesis and assembly, and (6) budding.
1. Binding and entry. Two important events in this process are attaching to the cell receptor,
and fusion. As mentioned before, the virus uses the viral gp120 to attach to the receptor CD4. Once
attached, the viral envelope modifies its structure, allowing part of the gp120 to interact with a coreceptor, creating a more stable attachment, and this double attachment permits the gp41 to
penetrate the host cell membrane. The gp41 contains a fusogenic hydrophobic peptide that causes
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fusion of the viral membrane and the host cells membrane, allowing the transmembrane crossing
of the viral capsid [65, 70].
2. Uncoating. Once inside the cell, uncoating is the process by which the viral RNA is
released from the capsid. After uncoating, the viral RNA is in the cytoplasm of the host cells and
is ready to be retro transcribed by the reverse transcriptase [71].
3. Reverse transcription. The reverse transcription of the viral RNA into proviral DNA is
a process accomplished by the enzymes reverse transcriptase and integrase. In the cytoplasm, the
reverse transcriptase starts the reverse transcription of the viral single strand RNA and produces a
complementary DNA strand, creating a double strand RNA/DNA hybrid. The reverse transcriptase
has a ribonuclease active site that breaks down the RNA strand in this hybrid molecule, then a new
DNA strand is produced that complements the first, creating a double strand DNA (dsDNA)
provirus [64, 72].
4. Integration. The dsDNA provirus is integrated into the host genome by integrase. This
enzyme has the capacity to cleave nucleotides located at the 3’ ends on both sides of the provirus,
which then generate modified ends that will allow the provirus to integrate. Integrase also is in
charge of transporting the provirus into the nucleus of the host cells and facilitate its integration.
All this is achieved by forming a complex, named pre-integration complex (PIC), with other viral
proteins (including Vpr and matrix proteins), as well as host proteins. The PIC enters the nucleus
through a nuclear pore, allowing the delivery and integration of the viral DNA [64, 73].
5. Protein synthesis and assembly. Integration and expression of the provirus require that
the host cell is in an activated state since the virus requires the use of the cell’s machinery to
produce its own proteins. Transcription of the integrated provirus results in the production of a full
RNA viral genome. In order to produce the proteins necessary to complete the HIV replication
21

cycle, the viral genome needs to undergo the process of splicing. This process is controlled by a
secondary RNA structure, cis-acting regulatory sequences that have the capacity to bind splicing
factors, and the viral protein Rev [74]. More than 40 different messenger RNAs (mRNAs), derived
from the full transcript viral RNA after the process of splicing, have been identified, and these
transcripts are the ones used by the cell machinery to produce viral proteins [75].
When the synthesis of viral proteins starts, the proteins Tat and Rev are initially produced,
which have important regulatory functions in this process. Tat attaches to the viral mRNA and
stimulates transcription and the production of long RNA transcripts, while Rev facilitates the
transcription of short RNA transcripts, the production of viral enzymes and structural proteins, and
inhibits the production of regulatory proteins, promoting the formation of mature viral particles.
Proteins derived from the genes gag, pol, and env will form the new viral particles. These proteins
are initially produced as polyproteins and are processed to be individually functional (as described
in the genome section) before the process of budding [76].
Out of all the transcripts produced, about half stay as a full transcript and are never spliced.
These molecules are transported to the cytoplasm, where they can be used as mRNA to produce
viral proteins or as genomic RNA for the production of new viral particles [75]. Assembly of a
new viral particle starts with the combination of two viral RNA strands that assemble together with
replication enzymes, which complex is in turn surrounded by core and capsid proteins that, after a
unique net of interactions, will result in the formation of the viral capsid. At this point, the capsid
has become what is called an immature viral particle, and it will migrate to the cell surface.
6. Budding. Once the viral particles reach the cell membrane, the virus will bud through
the cell membrane, acquiring its envelope, and is ready to infect other cells. In T lymphocytes,
budding occurs at the cell surface and the viral particles are released to the exterior of the cells,
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but in macrophages and monocytes, the budding process is oriented into vacuoles located in the
cytoplasm, that will later be released to the exterior of the cell. A representation of the main events
of the HIV replication cycle are illustrated in Figure 8.

Figure 8. HIV replication cycle. Adapted from “HIV sites for Therapeutic Intervention”, by BioRender.com
(2022). Retrieved from https://app.biorender.com/biorender-templates

2.5 Viral protein R
Many features of viral protein R (Vpr) have shown that is very important to the virus.
Although not all of its functions have been determined, many works have shown its participation
in the replication cycle, as well as its importance in the pathogenesis of the virus. The first insight
into this is that Vpr is incorporated in the viral particle (at an estimated number of 275 proteins per
virion), which suggests that it participates in the first steps of the infection of the host cell [77, 78].
Vpr is present in both human immunodeficiency viruses (HIV-1 and HIV-2), as well as in all
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simian immunodeficiency viruses (SIV) [79]. Importantly, it has been shown that Vpr is highly
conserved among several types of lentiviruses [80]. With the exception of this genus, Vpr does not
have a high degree of sequence homology with any other known protein [81].
Vpr is encoded by the vpr gene, and is composed of 96 amino acids (Table 3) with an
estimated molecular weight of 14 kDa [82]. The three-dimensional structure of the protein is
shaped by three bundled α-helices located between the positions 17-33, 38-50, and 55-77 [83]. The
C-terminal domain is positively charged and contains six arginine residues between positions 73
and 96; the N-terminal domain is negatively charged and presents four conserved prolines at
positions 4, 10, 14, and 35 (Figure 9) [84, 85]. Importantly, it has been shown that Vpr has the
capacity to associate to itself, forming dimers, trimers, and multimers, however, many of the
possible functions of these associations are yet to be elucidated [86].

Figure 9. Nuclear magnetic resonance (NMR) structure of HIV-1 protein Vpr
Source: Images created using Mol* should cite the PDB ID, the corresponding structure publication, Mol* (D. Sehnal,
S. Bittrich, M. Deshpande, R. Svobodová, K. Berka, V. Bazgier, S. Velankar, S.K. Burley, J. Koča, A.S. Rose (2021)
Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids
Research. doi: 10.1093/nar/gkab314), and RCSB PDB.
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Table 3. HIV-1 Vpr protein sequence
HIV-1 Vpr protein sequence
MEQAPEDQGPQREPYNDWTLELLEELKNEAVRHFPRIWLHSLGQHIYETYGDTWTGV
EALIRILQQLLFIHFRIGCRHSRIGIIQQRRTRNGASKS
Source: Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) - NMR structure of
the HIV-1 Regulatory Protein Vpr, PDB DOI: 10.2210/pdb1M8L/pdb BMRB:4257
https://www.rcsb.org/structure/1M8L.

One of the most important functions of Vpr is its contribution to the nuclear transport of
the PIC. It is thought that Vpr is one of the main regulators of PIC transport that is in charge of
carrying the viral genomic DNA to the nucleus of the cell. Apparently, Vpr creates a link between
the PIC and the nuclear import machinery of the host cell, which process is vital for the replication
of the virus [87, 88]. One example of this is that Vpr is required for efficient viral replication in
nondividing cells such as macrophages [81].
One unique property of Vpr is its capacity to inhibit host cell proliferation, a process
referred to as cell cycle arrest [89]. When T lymphocytes are newly infected and undergo cell
replication, due the activity of Vpr, these cells are not capable of finishing the cell cycle, and they
are “arrested” at the G2-M phase of the cycle [90]. The capacity of Vpr to perform cell cycle arrest
is conserved among primate lentiviruses (HIV and SIV), once more indicating that this protein is
very valuable to the virus [80, 91]. It is not well understood how and why the virus stops the cells
at this specific point in the replication cycle, however, HIV-1 gene expression is driven by the 5’
LTR, and this promotor seems to be more active in G2 phase, so it creates a situation that is
favorable for transcription of the viral genome [92].
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One possible explanation of the mechanism by which Vpr is capable of stopping the cell
cycle was published by Shimura et al. (2011). They explained that Vpr can disrupt the formation
of heterochromatin by inducing displacement of heterochromatin protein 1-α (HP1-α), causing
premature sister chromatid separation, leading to the halting of the cell cycle [93]. In the cell, two
proteins are in charge of regulating cell cycle arrest at phase G2 provoked by DNA damage: the
phosphatidylinositol 3-kinase-related kinase (ATR) and ataxia-telangiectasia mutated kinase
(ATM) [94]. If Vpr is actually damaging DNA, that is one possible path that would lead to cell
cycle arrest, additionally, incomplete reverse transcription can be detected as DNA damage
possibly triggering a similar response. Other studies have shown that Vpr binds to the adaptor
DCAF1 of a cullin 4a/DDB1 E3 ubiquitin ligase and recruits an unidentified cellular factor that is
necessary for the transition of the G2 phase to M phase of the cell cycle. It is believed that the
recruitment of this factor leads to its degradation, its subsequent absence then results in the
incapacity of the cell to continue the cell cycle [95, 96].
As we have seen, Vpr is a multitasking protein that performs important functions in the
viral replication cycle and the overall pathogenesis of HIV, nevertheless, its most notable ability
is that of inducing cell death. As a disease, infection with HIV-1 is characterized by an important
depletion of CD4+ T cells that leads to the development of AIDS, and Vpr is an active participant
in this process. Several studies have shown that Vpr has the capacity to induce apoptosis, but the
process by which this is achieved is not completely elucidated [97-99]. Importantly, induction of
apoptosis by Vpr has been demonstrated in different cell types, including neuronal cells, primary
lymphocytes, and other mammalian cells. [93, 96, 97]. One mechanism proposed by Jacotot et al.
(2000), using a synthetic Vpr-derived peptide (Vpr52-96), showed that Vpr binds to the
intermembrane face of the adenine nucleotide translocator (ANT) on mitochondria, causing
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mitochondrial membrane permeabilization (MMP), a process that triggers the release of proapoptotic proteins like cytochrome C [100]. Also, it has been demonstrated that Vpr has the
capacity to directly phosphorylate cell cycle regulators like the checkpoint kinase 1 (Chk1) leading
to apoptosis [101]. Another group (Andersen et al. 2006) showed that the apoptosis regulator Bax
is also involved in the induction of apoptosis, and the presence of ANT is not necessary in this
pathway. They also proposed that entry into the G2 phase of the cell cycle is required for Vpr to
induce apoptosis, and that this process is the consequence of a prolonged cell cycle arrest at phase
G2 [102]. This mechanism has been demonstrated specifically in T cell lines, fibroblasts, and
primary peripheral blood lymphocytes [103, 104]. Furthermore, in a humanized mouse model
(hematopoietic stem cell-transplanted), it was shown that Vpr induces cell cycle arrest and
apoptosis, predominantly in proliferating CD4+ CCR5+ T cells [105].
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Section III - Treatment

3.1 Immune evasion
When pathogens cross natural human physical barriers (skin and mucous membranes), our
body has the ability to recognize them as a potential threat, this process is carried out by special
cell receptors such as the pattern recognition receptors (PRRs) located on the cell membrane and
in the cytoplasm, or that can be secreted from the cell [106]. These receptors have the capacity to
identify specific conserved motifs of proteins and foreign nucleic acids from the invaders. These
recognizable molecules are denominated pathogen-associated molecular patterns (PAMPs) [107].
Some of the most important PRRs are denominated toll-like receptors (TLRs), including toll-like
receptor 2 (TLR2) and toll-like receptor 4 (TLR4) that have the capacity to identify viral proteins
[108, 109], and toll-like receptor 7 (TLR7) and toll-like receptor (TLR8) that are capable of
detecting single-stranded RNA (ssRNA) [110]. Additionally, viral PAMPs can be recognized by
receptors such as RIG-like receptors (RLRs) and C-type lectin receptors (CLRs). RIG-I and MDA5
(both RLRs) are able to recognize 5′ phosphorylated double strand RNA (dsRNA), whereas DCSIGN (a CLR) can recognize viral envelope glycoproteins [111].
When viral PAMPs have been recognized, PRRs send signals that turn on the expression
of the molecules necessary to mount an immune response. If TLRs are activated, their intracellular
dominion binds MyD88 activating mitogen activated protein kinase (MAPK) which is necessary
for the activation of nuclear factor kappa B (NF-κB). This transcription factor promotes the
production of pro-inflammatory cytokines and interferon regulatory factor (IRF) [112, 113]. One
the most specific responses that cells have against viral infections are interferons (IFNs), for
example, type I interferons act as antiviral agents, and can promote maturation of dendritic cells,
as well as regulate the function of natural killer cells, macrophages, T and B cells [114, 115].
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As do many retroviruses, HIV-1 has the capacity to evade the immune system, establishing
a long-term infection. To accomplish this, HIV-1 uses many strategies that help it to go into hiding
and even stop cellular components designed for its elimination. For instance, HIV-1 has the
capacity to down regulate the production of INFs; the specific steps by which this is accomplished
is not well understood, but it was documented that the glycoprotein gp120 has the capacity of
blocking the activity of cytokines by interfering with the activation of toll-like receptor 9 (TLR9)
in plasmacytoid dendritic cells (pDCs) [116].
The main resources HIV-1 has to avoid immune recognition are the viral accessory
proteins, used by the virus in some cases to down regulate or to eliminate host cells proteins
designed to stop viral replication. The viral protein Nef, for example, can down regulate the
intracellular trafficking of surface proteins that participate in immune recognition, like CD4, and
the major histocompatibility complex class I (MHC I) in T cells and macrophages [117]. Along
with Nef, Vpu has showed the capacity to reduce expression of CD4 by recruiting a cullin1-Skp1
ubiquitin ligase complex to the cytoplasmic tail of CD4 in the endoplasmic reticulum, inducing its
degradation [118]. Also, Vif is able to counteract the function of the protein apolipoprotein B
mRNA-editing enzyme catalytic polypeptide-like 3G (A3G), which can induce mutations on
polynucleotides (like on viral transcripts) by deaminating cytidine to uridine [119, 120]. When Vif
is not present, A3G is incorporated into new budding viruses and is taken to the next cell to be
infected, where it deaminates cytidine in nascent minus (first) strand reverse transcripts [119-121].
On the other hand, when Vif is present, it can recruit a cullin-RING ubiquitin ligase that is used to
degrade A3G [122].
In the same way as other viral proteins, Vpr presents the attribute of recruiting a cullinRING ubiquitin ligase, in this case the cullin4A-DDB1 complex, that links the receptor DCAF1 to
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Vpr through the DDB1 portion of the complex [95, 96]. When the link between Vpr and DCAF1
is prevented, Vpr is not able to induce G2 arrest [123]. It is possible that there are proteins targeted
by the cullin4A-DDB1 complex carried by Vpr that, if not degraded, could stop the interaction
between Vpr and DCAF1; in this case, these proteins could be a key mechanism of avoiding G2
arrest.
Vpr uses many strategies to avoid and disrupt the immune response. As mentioned before,
NF-κB is an important transcription factor for the production of cellular messengers like cytokines
and chemokines in immunity. It has been shown that Vpr has the capacity to down regulate the
expression of chemokines in human primary lymphocytes and macrophages through its effect on
the transcription of NF-κB [124]. One of the most important cellular messengers, interleukin-12
(IL-12), which induces production of interferon-γ (IFN-γ), regulates the response of natural killer
cells and T cells, and plays an important role in linking innate and adaptative immunity, is also
suppressed by Vpr in monocytes [125, 126]. In a study by Majumder et at. (2007), it was shown
that Vpr selectively impairs maturation, production of cytokines, and antigen presentation in
dendritic cells, leading to the induction of apoptosis on CD8+ T cells, which process is
accomplished in part by the upregulation and secretion of tumor necrosis factor alpha (TNF-α)
[127].
Many are the tactics that HIV-1 uses to avoid immune recognition, however, what could
be the HIV-1 master key for immune escape is the capacity to go into latency. HIV-1 mainly infects
CD4+ T lymphocytes and monocytes/macrophages, but other cell types like natural killer cells,
dendritic cells, cervical epithelial cells, mastocytes, astrocytes, skin fibroblasts, microglia in the
central nervous system, bone marrow stem cells, etc., can be infected and serve as a reservoir of
the virus [128]. Despite the ability of the virus to infect different cell types, resting CD4+ T cells
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are the major cellular reservoirs for HIV-1 [129, 130]. Integration of the provirus into the host cell
genome, and lack of protein expression in this state, make the virus invisible to detect, and
unreachable by the immune system.

3.2 Therapeutics
HIV-1 treatment by way of viral replication strategy (retro transcription) has been
denominated antiretroviral therapy (ART). In 1987, the first approved drug to treat HIV-1 was
Zidovudine (ZDV), which belongs to a class denominated nucleoside reverse transcriptase
inhibitors (NRTI). The therapeutic target of this class of agents is the process of reverse
transcription; NRTI use analogues of nucleosides and nucleotides that are preferentially
incorporated into HIV-1 DNA and are able to terminate the synthesis of the viral DNA. At that
time, ZDV was a success because it was able to reduce the viral load, delaying disease progression
and increasing the survival prognosis of the patients [131]. However, the single use of this drug
did not provide a sustained viral suppression, requiring it to be combined with protease inhibitors
(PI). These inhibitors have the capacity to bind to proteolytic enzymes necessary for HIV-1
replication, blocking their function, but many of them have been associated with important side
effects in long-term treatments [132-134]. By using this combined therapy, the treatment was able
to achieve an important reduction of viral load, improve immune function, and diminish relapsing
of opportunistic infections [135, 136]. From the outset of this therapy, it was clear that it was
necessary to use different drugs with different targets within the viral replication cycle in order to
improve the efficacy of the treatment.
Another class of ART are the integrase strand transfer inhibitors (INSTI). As we know,
HIV-1 has the capacity to integrate its genome into the host cell, and this process is mainly carried
out by a viral integrase that binds to viral DNA and joins it with the host DNA. INSTI are drugs
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designed to prevent the formation of covalent bonds with host DNA, preventing the incorporation
of proviral DNA. Members of this class include raltegravir, elvitegravir, and dolutegravir, which
are functional, generally well tolerated, and safe [137].
Non-nucleoside reverse transcriptase inhibitors (NNRTI), is an ART class that, like NRTI,
targets the process of revers transcription, but these drugs target an active site on the enzyme that
induces conformational changes, leading to the inhibition of reverse transcription. Members of this
class efficiently suppress viral replication, limited only by drug interactions. An important
characteristic of these drugs is that they are highly metabolized by cytochrome P450 enzymes
(CYP450) [138]. An interesting strategy was the developing of entry inhibitors, which are not
designed to act on the viral replication cycle, but to prevent the internalization of the virus into the
cell. The main agent of this class is Maraviroc, which functions by binding to the CCR5 cell
receptor, preventing the entry of R5 tropic viruses, however, it does not stop the entry of viruses
that use the cell receptor CXCR4 (R4 tropic viruses). For this reason, before its prescription,
confirmation of viral tropism is required [139].
Combination of HIV-1 protease inhibitors, reverse transcriptase inhibitors, and/or integrase
inhibitors is denominated highly active antiretroviral therapy (HAART), currently is the most
effective HIV-1 therapy. Several antiretroviral drugs have been approved by the food and drug
administration (FDA) (Table 4), many of which target different steps of the viral replication cycle
(Figure 10), are highly efficient, and are shown to be mildly toxic. Despite not having a cure for
HIV-1, nowadays most patients can get the virus under control after starting HAART [20].
However, when treatment is discontinued, patients experience viral rebound, immune
decompensation, and clinical progression [140, 141].
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Table 4. FDA-Approved HIV drugs
Generic Name (acronyms)

Brand Name

FDA Approval Date

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Abacavir (abacavir sulfate, ABC)
Emtricitabine (FTC)
Lamivudine (3TC)

Ziagen
Emtriva
Epivir

December 17, 1998
July 2, 2003
November 17, 1995

Tenofovir disoproxil fumarate (TDF)

Viread

October 26, 2001

Zidovudine (azidothymidine, AZT, ZDV)

Retrovir

March 19, 1987

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Doravirine (DOR)

Pifeltro

August 30, 2018

Efavirenz (EFV)

Sustiva

September 17, 1998

Etravirine (ETR)

Intelence
Viramune XR
(extended release)
Edurant

Nevirapine (extended-release nevirapine, nvp)
Rilpivirine (rilpivirine hydrochloride, RPV)

January 18, 2008
March 25, 2011
May 20, 2011

Protease Inhibitors (PIs)
Atazanavir (atazanavir sulfate, ATV)
Darunavir (darunavir ethanolate, DRV)

Reyataz
Prezista

June 20, 2003
June 23, 2006

Fosamprenavir (FOS-APV, FPV)

Lexiva

October 20, 2003

Ritonavir (RTV).

Norvir

March 1, 1996

Tipranavir (TPV)

Aptivus

June 22, 2005

Fuzeon

March 13, 2003

Selzentry

August 6, 2007

Vocabria

January 22, 2021

Tivicay
Tivicay PD
Isentress
Isentress HD

August 12, 2013
June 12, 2020
October 12, 2007
May 26, 2017

Fusion inhibitors
Enfuvirtide (T-20)
CCR5 antagonists
Maraviroc (MVC)
Integrase Strand Transfer Inhibitor (INSTIs)
Cabotegravir (cabotegravir sodium, CAB)
Dolutegravir (dolutegravir sodium, DTG)
Raltegravir (raltegravir potassium, RAL)

Source: modified from: HIV Overview, FDA-Approved HIV Medicines https://hivinfo.nih.gov/understanding-hiv/factsheets/fda-approved-hiv-medicines
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Figure 10. Anti-HIV therapeutic sites. Adapted from “HIV sites for Therapeutic Intervention”, by
BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates

3.3 Vaccine development
When properly used, ART is highly efficacious in preventing HIV-1 transmission in
different settings, including sexual transmission and mother to child transmission, as well as in
pre- and post-exposure [142-145]. Despite the positive prognosis when a patient is under ART,
following a lifelong treatment can be rigorous, and in many instances it represents a substantial
cost, especially in some high-burden, low- and middle-income countries [146]. As Fauci and
Marston expressed (2014): “even if HIV prevention efforts were optimally implemented to achieve
a new infection rate of near zero, recidivism could threaten this success [147].” The development
of an effective vaccine is necessary to end the global HIV pandemic.
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The first HIV-1 phase 3 trials were VAX003 and VAX004, carried out between the years
2004-2005. In these studies, prevention of HIV-1 infection was analyzed in high risk participants
from Thailand and the Americas, and in both trails, the results showed no prevention of infection
and no significant effect on viral load or CD4+ T cell count [148].
A promising trial, known as the RV144 Thai trial, was conducted by the United States
Army and the Thai Ministry of Public Health between the years 2003-2009 in Thailand. In this
study, the efficacy of the combination of two HIV vaccines (ALVAC-HIV and AIDSVAX B/E)
to prevent HIV infection was analyzed. During the time period of the study, 58.2% of participants
reported higher-risk behavior at least once, and statistical analysis estimated that the vaccine
efficacy was 60.5% through the 12 months after initial vaccination, but declined to about 31% at
a time point of 3.5 years post-inoculation [149]. The results of this trial kindled the hope of finding
an effective vaccine, and two more trials, RV305 and RV306, were a follow-up on participants of
trial RV144. RV305 enrolled vaccinated participants from trial RV144 after six to eight years
without HIV-1, the purpose of the trail being to determine if it were possible to improve the
durability of the response by boost immunizations. The study showed that the immunization in
trial RV144 had induced memory responses, and that repeated boosting induced higher
immunogenicity than the immunization received at trial RV144 alone [150, 151]. RV306 followed
the RV144 immunization regimen adding boost immunizations at time points of 12, 15, or 18
months. The purpose of this study was to determine the optimal boost timepoint, and the response
was measured at 24 months after the start of the trial. The importance of timed boosting was
demonstrated by lower plasma IgG responses in participants receiving the boost at 12 months, and
an increased CD4+ T-cell functionality in participants receiving later boosting at 15 and 18 months
[152].
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Other trials have used different strategies, primarily focusing on producing T-cell
responses with vector-based vaccines, without much success. Examples include the STEP trial
(HVTN 502, 2008) [153], that had to stop when an “interim analysis revealed an infection rate in
per protocol male vaccinees double that of placebo recipients” [154]; and the Phambili trial (HVTN
503, 2011) [155], that “was terminated early based on the results of the STEP trial, and preliminary
data revealed a higher incidence of HIV infection in the vaccinated group compared to placebo,
without impact on viral load or disease progression” [154]. Several groups are in pursuit of
developing a safe and effective vaccine, and many trials have achieved notable results like the ones
presented in trail RV144, nevertheless the Achilles heel of most of these efforts has been a lack in
viral load reduction and insufficient protection against infection.
As of July 2022, there is no HIV-1 vaccine available, however other strategies are being
developed to reduce HIV-1 infection. One approach, denominated antibody mediated protection
(AMP), uses broadly neutralizing antibodies (bNAbs). These antibodies are not commonly found
in HIV-1 infected patients, for their production it is required to prime B cells encoding bNAb
precursors, followed by immunogens to aid in affinity and immune recognition. In a trial designed
to analyze the capacity of bNAbs to prevent HIV-1 acquisition, VRC01 (a bNAb) showed an
efficacy of 75% in prevention against VRC01-sensitive virus, but did not show a significant
reduction in viral infection of non-sensitive virus vs placebo [156]. The molecular biology area is
also interested in developing an effective HIV-1 vaccine is using messenger RNA (mRNA). One
study using a single immunization of a self-amplifying mRNA (saRNA) was able to induce CD4+
and CD8+ T cells in mice, and this cellular response was maintained for at least 22 weeks postvaccination [157].
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3.4 Disease progression
When a person is infected with HIV-1, the time frame to develop AIDS is known to be
extremely variable between individuals. There are many factors that could contribute to the
development of AIDS, including age, general health, nutritional status, virologic factors, natural
response of the host, etc., and the reason why some patients develop AIDS quicker than others is
not completely understood. Two indicators of the progression to AIDS are: the decline of immune
response (especially the depletion of CD4+ cell populations), and an increase in the replication rate
of the virus [158]. Regarding the time period of disease progression, it has been identified that a
small percentage of untreated HIV-1 infected patients do not develop AIDS, being generally
medically healthy, presenting a high CD4+ count and a low viral load. A patient in this category is
a long-term non-progressor (LTNP) [159].
It is interesting to question the molecular participation of the virus in LTNP patients,
because depletion of CD4+ cells in infected patients has been attributed to viral proteins such as
Nef, Tat, Env, and Vpr, since some of them present apoptotic and anti-apoptotic effects [160]. The
contribution of Vpr to the depletion of CD4+ cells has called the attention of many different
research groups, due to the variety of ways it participates in the viral replication cycle and cell host
modulation. Analysis of the participation of Vpr in cell depletion paid off when Lum et al. (2003)
published that in about 80% of LTNP patients, there is a point mutation at position 77 where
arginine (R) is substituted by glutamine (Q) [161]. The presence of the Vpr R77Q mutation in most
LTNP patients gives us a hint about its possible involvement in the development of this phenotype,
and an association between the mutation and phenotype has been demonstrated by some groups
[162, 163], however other groups have found no correlation [164, 165].
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Some other Vpr mutations have been associated with other progression phenotypes. A
mutation where an arginine (R) located at position 36 is substituted by tryptophan (W) has been
associated with patients that present a rapid progression to AIDS, and these patients have been
denominated rapid progressors (RP) [163].
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RESEARCH AIM
The aim of this study is to identify if there are significant differences in the cytopathic
effect caused by HIV-1 expressing different isoforms of the viral protein R (Vpr) on different cell
lines and primary CD4+ T cells. Cell death and induction of apoptosis induced by HIV-1 expressing
Vpr wild type (WT), two isoforms of Vpr expressing mutations R77Q and R36W, and a Vpr
knockout is compared, with the purpose of better understanding the participation of these known
mutations in cell depletion.
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HYPOTHESIS
It is hypothesized that the human immunodeficiency virus type 1 (HIV-1), through the viral
protein R (Vpr) expressing isoform R77Q, has the capacity to significantly induce apoptosis in
host cells, delaying cell death, process that has been correlated to patients that are HIV-1 positive
and remain healthy for long periods of time without medications (long-term non-progressors).

40

EXPERIMENTAL APPROACHES
Section IV - Materials and Methods

4.1 Plasmids
Vpr wild type (WT): the molecular clone pYK-JRCSF to produce HIV-1 strain JR-CSF
expressing Vpr WT was obtained through the NIH HIV Reagent Program, Division of AIDS,
NIAID, NIH: Human Immunodeficiency Virus 1 (HIV-1), Strain JR-CSF Infectious Molecular
Clone (pYK-JRCSF), ARP-2708, contributed by Drs. Irvin S. Y. Chen and Yoshio Koyanagi.
Construction of HIV-1 Vpr mutants R77Q and R36W: the region surrounding the vpr gene
was cloned into the pUC19 vector (Addgene #50005) using the EcoRI and SbfI sites (New England
Biolabs) for site directed mutation (SDM). SDM was accomplished using back to back primers
with single point mismatches; the sequences used to induce this mutation are presented in Table
5. After SDM, the vpr gene was removed from pUC19 using the same enzymes and ligated into
the pYK-JRCSF plasmid. The desired mutation and in-frame ligations were confirmed by Sanger
sequencing.
Construction of HIV-1 Vpr Knockout: the region surrounding the vpr gene was treated as
described before to change the ATG codon to GTG to produce the knockout mutant; the sequences
used to induce this mutation are presented in Table 5. After SDM, the vpr gene was removed from
pUC19 using the same enzymes and ligated into the pYK-JRCSF plasmid. The desired mutation
and in-frame ligations were confirmed by Sanger sequencing.
The induced point mutations do not affect any overlapping genes in the viral genome. Plasmids
used in this this study were constructed by Antonio Solis Leal as part of his PhD dissertation.

41

Table 5. Primers used for Site Directed Mutation
HIV-1 Mutant
Vpr R36W

Vpr R77Q

Vpr Knockout

Primers
Forward ACATTTTCCTTGGATCTGGCTC
Reverse CTAACAGCTTCATTCTTAAG
Forward ATTGGGTGTCAACATAGCAGAATAG
Reverse TCTGAAATGAATAAACAGCAG
Forward CAGAGGACAGGTGGAACAAGC
Reverse TCAGTTTCCTAACACTAGGC

4.2 Cell culture
Primary Cells
Peripheral blood mononuclear cells (PBMCs) from whole blood were isolated by density
gradient centrifugation over Ficoll using SepMate™-50 tubes. CD4+ T cells were isolated from
PBMC, using the EasySep™ Human CD4+ T Cell Isolation Kit (StemcellTM Technologies Catalog # 17952) following the manufacturer instructions. Primary CD4+ T cells were maintained
at 37 ºC, 5% CO2 in RPMI medium (Mediatech), supplemented with 10% FBS, 1% glutamine,
and 1% penicillin/streptomycin (P/S).
Cell lines
HEK 293FT cells were maintained at 37 ºC, 5% CO2 in DMEM (Sigma-Aldrich),
supplemented with 10% fetal bovine serum (FBS; HyClone), 2% glutamine, 1% G418 (Teknova),
and 1% penicillin/streptomycin (P/S).
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Ghost R3/X4/R5 cells were maintained at 37 ºC, 5% CO2 in DMEM, supplemented with
10% FBS, 1% P/S, 500 μg/mL G418, 100 μg/mL hygromycin, and 1 μg/mL puromycin. Ghost
cells were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
GHOST (3) CCR3+ CXCR4+ CCR5+ Cells from Drs. Vineet N. Kewal Ramani and Dan R.
Littman (cat# 3943).

4.3 Transformation
One-shot Stbl3 E. coli cells (Invitrogen C737303) were used for all transformations. Cells
were independently transfected with 5 µl of selected plasmids, incubated 30 min on ice, and heat
shocked at 42 oC for 90 seconds. Bacteria were left to rest for 45 min and then plated on LB agar
plates containing ampicillin at a concentration of 100 µg/mL. Plates were incubated at 37 oC
overnight and resistant colonies harboring the plasmids were selected for isolation.

4.4 Plasmid characterization
Transformed colonies harboring plasmids were cultivated in LB media with ampicillin 100
µg/mL at 37 oC and 200 rpm overnight. Plasmids were purified using the E.Z.N.A.® Plasmid DNA
Maxi Kit (Omega bio-tek SKU: D6922-02) following the manufacturer instructions.
Plasmids were digested with EcoRI-HF® following the manufacturer instructions, and
characterized by agarose gel electrophoresis.

4.5 Transfection
Following the calcium chloride method (Protocol 1), 20 µg of plasmid containing HIV-1
proviral cDNA for each virus was used to transfect HEK 293FT cells (T-75 flask 60% confluent).
Water diluted plasmid DNA at the appropriate concentration was mixed with 2 M calcium chloride
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and added to the equivalent volume of 2X HEPES-buffered saline (HBS) to produce a
DNA/calcium phosphate precipitate. The precipitate was added to the cell culture, and the virus
was harvested 48 hours post-transfection.

4.6 Viral titers
The viral titers were determined using Ghost R3/X4/R5 cells that produce green fluorescent
protein (GFP) after being infected with selected lentiviruses. 5 x 104 cells were infected for 2 hours
using different dilutions of each virus in the presence of 20 µg/mL of polybrene. The expression
of GFP was analyzed 48 hours post-infection by flow cytometry, and the median tissue culture
infectious dose (TCID50) was calculated using the Reed-Muench method.

4.7 Infection assays
The time frame of infection was 2 h for all the infection assays. Primary cells were infected
at a multiplicity of infection (MOI) of 0.01 in the presence of 10 µg/mL of polybrene. Ghost cells
were infected at a MOI of 0.03 in the presence of 20 µg/mL of polybrene. Cells were collected on
specified days of infection for each assay and analyzed for viability, apoptosis, and HIV-1
infection (Protocol 2 and Protocol 3).
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RESULTS
Section V - Results and Analysis

5.1 Plasmids and transfection
Plasmids for HIV-1 strain JR-CSF WT, R36W, R77Q, and Vpr knockout (Null) were
transformed into one-shot Stbl3 E. coli cells. The molecular clone pYK-JRCSF that harbors this
strain about 15 kilobases in size. This plasmid is a construct derived from the plasmid pBR322
that confers ampicillin resistance. Resistant colonies were selected for each virus, expanded, and
plasmids were isolated. After isolation, plasmids were digested with the restriction enzyme EcoRI
and analyzed by electrophoresis. The Vpr WT, R36W, R77Q, and Vpr Null plasmid bands
harboring HIV-1 and mutants were identified in the expected position according to the fragment
size Figure 11-A.
B

A

Figure 11. Plasmids for transfection of HEK 293FT cells. A) Electrophoretic analysis of the different
plasmids harboring HIV-1 viruses. B) HEK 293FT cells used for transfection.

To produce viral stocks, plasmids harboring each virus were independently used to
transfect HEK 293FT cells following the calcium chloride method. Viruses were collected and
stored at – 80 oC.
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5.2 Viral titers
To determine the titer of the viral stocks, Ghost R3/X4/R5 cells were infected. 48 hours
post-infection, expression of green fluorescent protein was analyzed by flow cytometry to identify
fluorescence Figure 12. The median tissue culture infectious dose (TCID50) was calculated using
the Reed-Muench method.
B

A

C

Figure 12. Expression of GFP in Ghost R3/X4/R5 cells. A) Infected Ghost R3/X4/R5 cells under light
microscopy. B) Infected Ghost R3/X4/R5 cells under ultraviolet microscopy. C) From left to right:
Uninfected Ghost R3/X4/R5 cells do not express GFP; GFP expression in Ghost R3/X4/R5 cells infected
with HIV-1 Vpr isoform R77Q; Population of Ghost R3/X4/R5 cells expressing GFP infected with HIV-1
Vpr knockout.

46

5.3 Isolation of Primary CD4 cells
To obtain primary CD4+ cells, PBMCs from whole blood were isolated by density gradient
centrifugation. Primary CD4+ T cells were isolated from PBMCs by immunomagnetic negative
selection, and their purity was determined by flow cytometry double positive staining, using an
antibody against CD3 conjugated with the dye Pacific Blue in combination with an antibody
against CD4 conjugated with the dye PE-Cyanine7. Purity for one representative sample was
99.71% CD3+/CD4+ cells (Figure 13).

C

B

CD3

A

CD4

CD3

D

CD4
Figure 13. Characterization of CD4+ primary cells. A) Unstained isolated cells are double negative for
CD3 and CD4. B) Single CD4 stained positive cells. C) Single CD3 stained positive cells. D) Double
stained double positive CD3+/CD4+ cells.

47

5.4 Cell Viability
Primary cells behave differently than a cell line. Since they are not immortalized and lack
many of the natural environmental elements that keep them thriving, their viability when contained
in vitro is limited. For this reason, the viability of the isolated CD4+ cells was assessed, to
determine the percentage of cells that could naturally die due the maintenance of these cells in
vitro. Isolated cells were stained at two different time points after isolation (Day 5 and Day 7) to
determine the percentage of Live/Dead cells. Cells were stained with fixable viability dye
(LIVE/DEAD Fixable Far Red Dead Cell Stain) and analyzed by flow cytometry. In cells with
compromised membranes, the dye reacts with free amines both in the cell interior and on the cell
surface, yielding intense fluorescent staining. In viable cells, the dye's reactivity is restricted to the
cell-surface amines, resulting in less intense fluorescence. After 5 days, 83.52% of the cells were
identified as healthy and 6.55% dead. After 7 days, 74.48% of the cells were identified as healthy
and 13.26% as dead (Figure 14).

A

B

Figure 14. Viability of primary CD4+ Cells. A) Cell viability staining 5 days after isolation, at this time
point 83.52% of the cells are considered healthy. B) Cell viability staining 7 days after isolation, at this time
point 74.48% of the cells are considered healthy. Cells located out of identified populations in A and B,
generally present structural degradation, this condition will incorporate less dye than dead cells. Cells in
this area a are not considered in any of both populations.
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5.5 Identification of apoptosis
Identifying if a cell is undergoing the process of apoptosis can be achieved by staining the
cells with Annexin V. This molecule is a human anticoagulant Ca2+ dependent phospholipidbinding protein that has a high affinity for the anionic phospholipid phosphatidylserine (PS). In
normal healthy cells, PS is located on the cytoplasmic surface of the plasma membrane. However,
during apoptosis, the plasma membrane undergoes structural changes that include translocation of
PS from the inner to the outer leaflet (extracellular side) of the plasma membrane, allowing their
recognition by staining the cells with Annexin V. There is not a well stablished protocol to induce
apoptosis in mammalian cells, however, it has been reported that dimethyl-sulfoxide (DMSO) at
concentrations of 2% - 4% has the ability to induce apoptosis in mammalian cells [166, 167].
To identify apoptosis, Ghost R3/X4/R5 cells were treated with 2.5% DMSO for 48 hours
and compared with cells treated with polybrene, a mildly cytotoxic agent (Figure 15). Cells treated
with polybrene presented 10.8% apoptotic cells after 48 hours, while cells treated with 2.5%
DMSO presented 42.27% apoptotic cells.

B

A

Figure 15. Identification of apoptotic cells. A) Ghost R3/X4/R5 cells treated with polybrene induced
apoptosis in 10.8% of cells (lower right quadrant). B) DMSO treatment induced apoptosis in 42.27% of
cells (lower right quadrant).
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5.6 Infection of CD4+ primary cells
To identify any differences in the cytotoxicity and induction of apoptosis between HIV-1
Vpr WT, R36W, R77Q and Vpr Null in primary CD4+ cells, cells were infected at a MOI of 0.01
for 2 hrs. and stained at day 3 and day 5 post-infection, to determine viability (live/dead fixable
far red stain), and apoptotic cells (Annexin V conjugated with fluorescein isothiocyanate (FITC)).
These time points were selected based on previous experiments from our laboratory, that showed
that infection and viral replication of HIV-1 Vpr WT, R36W, R77Q and Vpr Null can be detected
during the first seven days post-infection in a T cell line.
After day 3 post infection, we observed significant differences in the induction of apoptosis
among the different strains of HIV-1 Vpr variants. At this time point, R36W significantly induced
more apoptosis than Vpr null and that R77Q, and R77Q significantly induced more apoptosis that
Vpr null. It is notable that none of them presented significant differences when compared to WT.
At day 5 post infection, the only significant difference between the strains was R77Q, which
significantly induced more apoptosis than the WT. It is important to mention that despite not
having a significant difference, R77Q induced more apoptosis than R36W at level of confidence
of p-value = 0.06, a correlation between these results is presented in Figure 17.
Infection of the primary cells was determined by staining for the viral protein P24 at the
two indicated time points. Infection of primary cells by HIV-1 JR-CSF is conditioned by the
expression of the co-receptor CCR5+ because it is a R5 tropic virus. It has been described that in
healthy individuals the percentage of CD4+ CCR5+ T cells is on average 6.2% [168]. For this
reason, infection of primary cells at day 3 was low, HIV-1 WT was able to infect the most cells
with an average percentage of 3.44%, followed by R77Q with 1.68%, Vpr null 1.35% and R36W
1.28% (Table 6).
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At day 5 post infection, identification of viral protein P24 in was mostly under 1% with the
exception of R36W, possibly because the primary cells are not actively dividing, which is a
requirement for the virus to complete the replication cycle (Figure 16). Isolated T cells in many
studies are chemically activated to induce their proliferation. To better understand the participation
of Vpr in the induction of apoptosis, in this study the primary cells were not activated. The limited
number of cells expressing the receptor CCR5 is an important determinant to identify if different
viruses expressing Vpr WT, R36W, R77Q and Vpr null have a significant effect in cell viability
and induction of apoptosis. For this reason, we decided to identify a model cell line that expresses
the co-receptor CCR5 allowing higher infection with HIV-1 JR-CSF. The model cell line with this
capacity is Ghost R3/X4/R5 cell line.

Figure 16. P24 positive primary CD4+ T cells at day 3 and day 5 post-infection. At day 5, there was a
significant reduction in the number of P24 positive cells for Vpr WT, R77Q, and Vpr null. Percentage of
infection for these strains is under 1%. The percentage of P24 positive cells did not have a significant
change from day 3 to day 5 for R36W. Data are representative of 3 independent experiments and error bars
indicate Standard Error (SE). * p-value < 0.05, ** p-value < 0.01.
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A

B

Figure 17. Induction of apoptosis by HIV-1 Vpr variants. HIV-1 Vpr WT, R36W, R77Q and Vpr Null were
used to infect primary CD4+ CCR5+ T cells at a MOI of 0.01, apoptotic cells were identified at day 3 and
day 5 post-infection. A) Day 3 post-infection: R36W induced significantly more apoptosis than R77Q and
Vpr null. At this time point also R77Q significantly induced more apoptosis than Vpr null. B) Day 5 postinfection: R77Q significantly induced more apoptosis than WT and induced more apoptosis than R36W
with a confidence of p-value = 0.06. Data are representative of 3 independent experiments and error bars
indicate Standard Error (SE). * p-value < 0.05, ** p-value < 0.01. See Table 6 for statistical analysis.
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Table 6. Statistical analysis of primary CD4+ CCR5+ T cells apoptotic and infected cells.
% APOPTOTIC CELLS DAY 3
1

2

3

UI

1.50

2.20

1.52

WT

0.52

1.02

R36W

1.19

R77Q
NULL

SD

SE

1.74

0.40

0.23

1.38

0.97

0.43

0.25

1.18

1.16

1.18

0.02

0.01

0.98

0.96

1.09

1.01

0.07

0.04

0.82

0.87

0.95

0.88

0.07

0.04

% APOPTOTIC CELLS DAY 5
1
2
3
UI
1.47
1.17
1.38
WT
0.91
0.94
0.89
R36W
0.79
0.63
1.00
R77Q
1.11
1.07
1.07
NULL
1.67
0.59
0.45

Avg

T-TEST DAY 3
R36W
R77Q
Null
WT
0.256483 0.441957 0.351783
R36W
0.037513 0.011931
R77Q
0.012348

T-TEST DAY 5
Avg
1.34
0.91
0.81
1.08
0.90

SD
0.15
0.03
0.19
0.02
0.67

SE
0.09
0.01
0.11
0.01
0.39

R36W
WT

R77Q

Null

0.236176 0.007333 0.490839

R36W

0.063206 0.419388

R77Q

0.338216

% P24 POSITIVE CELLS DAY 3
1

2

3

UI

0.82

0.64

0.74

WT

3.85

2.54

R36W

1.29

R77Q
NULL

Avg

SD

SE

0.73

0.09

0.05

3.92

3.44

0.78

0.45

1.51

1.05

1.28

0.23

0.13

1.65

1.64

1.75

1.68

0.06

0.04

1.36

0.83

1.86

1.35

0.52

0.30

SD

SE

% P24 POSITIVE CELLS DAY 5
1

2

3

Avg

UI

0.15

0.31

0.36

0.27

0.11

0.06

WT

0.34

0.36

0.55

0.42

0.12

0.07

R36W

1.40

1.33

1.47

1.40

0.07

0.04

R77Q

0.30

0.17

0.30

0.26

0.08

0.04

NULL

0.51

0.18

0.19

0.29

0.19

0.11
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Comparison P24 positive cells
day 3 and day 5
T-Test
1- 3.85
1- 0.34
WT
2- 2.54
2- 0.36
0.0095
3- 3.92
3- 0.55
1- 1.29
1- 1.40
R36W 2- 1.51
2- 1.33
0.2850
3- 1.05
3- 1.47
1- 1.65
1- 0.30
R77Q 2- 1.64
2- 0.17
0.0003
3- 1.75
3- 0.30
1- 1.36
1- 0.51
Null
2- 0.83
2- 0.18
0.0386
3- 1.86
3- 0.19

5.7 Infection of Ghost R3/X4/R5 cells
Ghost R3/X4/R5 cells constitutively express CCR5 allowing infection with R5 tropic
viruses. Cells were infected at a MOI of 0.03 for 2 hrs. and stained 48 hrs. post infection. The time
point of 48 hrs. was selected, because protocols to analyze infection of this cell line indicate that
48 hrs. is the optimal time to identify expression of GFP produced after infection with HIV. To
identify the effect of HIV-1 Vpr WT, R36W, R77Q and Vpr null, cells were stained to determine
viability (live/dead fixable far red stain), and apoptotic cells (Annexin V conjugated with Rphycoerythrin (R-PE)). Quantification of the percentage of infected cells was determined by
expression of GFP.
Expression of GFP was identified at 48 hrs. post infection, Vpr null significantly infected more
cells than all other strains, and R77Q was able to significantly infect more cells than R36W.

Figure 18. Expression of GFP in Ghost R3/X4/R5 infected cells after 48 hrs. HIV-1 Vpr WT, R36W, R77Q
and Vpr Null were used to infect Ghost R3/X4/R5, 48 hrs post-infection expression of GFP was analyzed
by flowcytometry, Vpr Null significantly infected more cells than the other strains, R77Q significantly
infected more cells than R36W. Data are representative of 3 independent experiments, error bars indicate
Standard Error (SE). * p-value < 0.05, ** p-value < 0.01. See Table 7 for statistical analysis.
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Table 7. Statistical analysis of Ghost R3/X4/R5 infected cells.
% INFECTED CELLS
1
2
UI
0.39
0.36

3
0.38

Avg
0.38

SD
0.02

SE
0.01

WT

12.37

29.82

21.20

21.13

8.73

5.04

R36W

26.50

21.68

16.47

21.55

5.02

2.90

R77Q

49.48

28.38

47.82

41.89

11.73

6.78

NULL

74.37

68.81

72.76

71.98

2.86

1.65

T-TEST INFECTION
NULL

0.000
0.008
0.002
0.014

WT

0.027 UI
0.479 R36W
0.106 R77Q

R36W

0.009 UI
0.053 R77Q

R77Q

0.013 UI

UI
WT
R36W
R77Q

55

Viability of Ghost R3/X4/R5 cells
Cells considered healthy 48 hrs. post-infection were identified using a live/dead fixable far
red stain. Vpr null presented significantly more healthy cells than Vpr WT and R36W. This was
an interesting outcome since the average infection presented by Vpr null is more than three-fold
that of Vpr WT and R36W, indicating that expression of Vpr could be the causal agent of the low
percentage of healthy cells. Absence of Vpr in Vpr null could be the reason why this strain
presented significantly more healthy cells, despite higher infection over all other strains.
Additionally, R77Q presented significantly more healthy cells than R36W, which was not
unexpected, since R36W has been related to RP patients and R77Q to LTNP patients. It is
interesting to find that in a cell line using an R5 tropic virus we are able to identify this difference
(Figure 19).

Figure 19. Healthy Ghost R3/X4/R5 cells 48 hrs. post-infection. Vpr null presented more healthy cells than
Vpr WT and R36W. R77Q significantly presented more healthy cells that R36W. Data are representative
of 3 independent experiments and error bars indicate Standard Error (SE). * p-value < 0.05, ** p-value <
0.01. See Table 8 for statistical analysis.
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Necrotic cells 48 hrs. post-infection were identified by staining cells with a live/dead
fixable far red stain. Reciprocally to healthy cells, those strains that presented more healthy cells
also presented fewer Necrotic cells. R77Q has significantly fewer necrotic cells than R36W; it is
important to consider that R77Q infected about two times fold more cells that R36W and Vpr WT.
R77Q presented fewer necrotic cells than Vpr WT with a p-value of p=0.08 confidence. R77Q
induces cell dead by necrosis about three folds less than R36W and Vpr WT.
Also, Vpr null presented significantly fewer necrotic cells than Vpr WT and R36W, but
the difference was not significant when compared to R77Q, suggesting that the cytopathic effect
of the R77Q mutation is comparable to the absence of Vpr in the Vpr null strain Figure 20.

Figure 20. Necrotic Ghost R3/X4/R5 cells 48 hrs. post-infection. Strain R77Q presents significantly fewer
necrotic cells than R36W and fewer necrotic cells than Vpr WT with a p-value of p=0.08. Vpr null presents
significantly fewer necrotic cells than R36W and Vpr WT. Not significant differences are identified
between R77Q and Vpr null. Data are representative of 3 independent experiments and error bars indicate
Standard Error (SE). * p-value < 0.05, ** p-value < 0.01. See Table 8 for statistical analysis.
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Table 8. Statistical analysis of viability Ghost R3/X4/R5 cells.
% HEALTHY CELLS
1
2
UI
93.91
93.32

3
93.62

Avg
93.62

SD
0.30

SE
0.17

WT

20.80

44.07

34.49

33.12

11.70

6.76

R36W

35.78

31.88

25.87

31.18

4.99

2.89

R77Q

79.43

44.71

77.85

67.33

19.61

11.33

NULL

87.52

80.84

87.40

85.25

3.82

2.21

T-TEST HEALTHY CELLS
R77Q 0.071

UI

0.094

WT

Null 0.028 UI
0.013 WT

0.047 R36W
0.094

R36W 0.001 UI

WT

0.006 UI

0.42 WT

0.002 R36W

Null

% NECROTIC CELLS
1
2
UI
1.34
1.83

3
1.59

Avg
1.59

SD
0.25

SE
0.14

WT

74.77

49.80

61.10

61.89

12.50

7.23

R36W

53.57

63.96

69.87

62.47

8.25

4.77

R77Q

6.42

45.98

8.73

20.38

22.20

12.83

NULL

3.82

8.42

3.03

5.09

2.91

1.68

T-TEST NECROTIC CELLS
R77Q

0.138 UI
0.083 WT
0.04 R36W

Null

0.078 UI

R36W

0.011 WT

0.003 UI
0.481 WT

0.004 R36W

0.152 Null
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WT

0.007 UI

Induction of apoptosis
To identify if different HIV-1 Vpr strains induce differing levels of apoptosis, Ghost
R3/X4/R5 cells were stained with live/dead fixable far red stain and Annexin V conjugated with
R-PE 48 hrs. post-infection. Cells with permeabilized membranes allow Annexin V to enter and
attach to phosphatidylserine inside cells; cells considered as apoptotic are those that do not have a
compromised membrane, and that after staining with the viability dye are classified as live cells,
and when stained with Annexin V are positive for this dye. We were able to identify that cells
infected with R77Q strain presented significantly more apoptosis than Vpr WT and R36W Figure
21. Vpr null had also significantly more apoptotic cells than Vpr WT. The average percentage of
apoptotic cells for R77Q was 10.88%, compared to 3.42% in Vpr WT, 4.00% in R36W, and 7.51%
in Vpr null, and 4.15% in uninfected population Table 9. There was not a significant different in
apoptotic cell between Vpr WT and R36W.
Interestingly, significant differences in apoptosis between different strains of HIV-1 Vpr
were clearer to identify when infection of cells was above 20% for all strains. Results obtained
from 3 independent experiments showed that when cells were infected at smaller percentages (Vpr
WT 7.69%, R36W 5.29, R77Q 7.90%, and Vpr null 16.19%), statistically significant differences
in the induction of apoptosis were only identified between two strains R77Q and R36W. As a result
of these experiments, R77Q induced significantly more apoptosis than R36W (See Table 10 and
Figure 22 in appendix). The conditions under which these experiments were carried out, were the
same conditions as the previously described representative experiment, viral infection time of 2
hrs., MOI of 0.03, time point for identifying viability and apoptosis of 48 hrs. post-infection.
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Figure 21. Apoptotic Ghost R3/X4/R5 cells 48 hrs. post-infection. R77Q significantly induces more
apoptosis than Vpr WT and R36W. Vpr null significantly induces more apoptosis than Vpr WT. Data are
representative of 3 independent experiments and error bars indicate Standard Error (SE). * p-value < 0.05,
** p-value < 0.01. See Table 9 for statistical analysis.

Table 9. Statistical analysis of apoptotic Ghost R3/X4/R5 cells.
% APOPTOTIC CELLS
1
2
UI
4.27
4.02

3
4.15

Avg
4.15

SD
0.13

SE
0.07

WT

2.44

4.86

2.95

3.42

1.28

0.74

R36W

9.41

1.31

1.29

4.00

4.68

2.71

R77Q

12.66

8.40

11.57

10.88

2.21

1.28

NULL

6.54

8.40

7.59

7.51

0.93

0.54

T-TEST APOPTOTIC CELLS
R77Q

0.015

UI

0.033

WT

0.039 R36W
0.101

WT

0.231

UI

R36W

0.436 R36W
0.003

0.481

UI

0.194 Null

Null

Null
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Null

0.015683

UI

DISCUSSION
In this study, we investigated the cytopathic effect of HIV-1 on the infection of primary
CD4+ CCR5+ T cells, and on the model cell line Ghost R3/X4/R5. The main focus of this study
lies in the comparison of two isoforms of HIV-1 Vpr: R36W, related to rapid progressor patients,
and isoform R77Q, related to long-term non-progressor patients. Based on the plasma membrane
integrity of infected cells, viable cells and cells undergoing the apoptotic process can be
differentiated from cells that died by necrosis, a process that is characterized by the loss of plasma
membrane integrity.
We have found that the level of infection in primary CD4+ CCR5+ T cells by R36W was
maintained from day 3 to the end time point of day 5 post-infection, while this was not observed
in the other strains. Comparable results for isoform R36W were obtained by the group of Hadi, et
al [163], where infection of PBMCs and replication kinetics of HIV-1 strain NL4-3 harboring
different Vpr mutations (R36W, L68M, R77Q and R85Y) was assessed at 2-day intervals after
infection (measuring the viral protein P24) with an endpoint of 8 days. In these experiments,
similar amounts of P24 were identified in PBMCs infected with R36W at days 4 and 6 postinfection, while in most of the other strains, P24 decayed from day 2 to days 4 and 6 [163]. This
same decay of infection was observed using our strain JRCSF in WT, R77Q, and Vpr null infecting
CD4+ CCR5+ T cells 5 days post-infection (Figure 16). In addition, previous results from our lab
showed that R36W has a higher replicative capacity in HUT78 T cells when compared to the other
strains (Antonio Solis-Leal). This capacity of R36W could be related to the sustained infection
levels that we identified in primary cells at the two time points.
Vpr isoform R77Q has been related to a higher induction of apoptosis, although
unexpectedly, at day 3 post-infection, R36W significantly induced more apoptosis than R77Q and
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Vpr null (Figure 17-A). However, 5 days post-infection, R77Q significantly induced more
apoptosis than Vpr WT and induced more apoptosis than R36W with a p value of p=0.06 (Figure
17-B). It is possible that the mechanism by which R36W induces cell death at an early point leading
to necrosis in these cells can be identified as apoptosis, or the sensitivity of the test did not allow
us to identify the expected results at this time point. The increase of apoptosis at day 5 allows us
to corroborate the correlation of mutation R77Q that has been made with this programmed cell
death [161].
To better understand our previous findings about the cytopathic effects of the isoforms
R36W and R77Q, we decided to infect the model cell line Ghost R3/X4/R5, which was selected
both for its capacity to express the receptor CCR5 and its permissiveness of infection with R5
tropic viruses. This allows us to target more cells than primary CD4+ CCR5+ T cells, and achieve
higher infection using the HIV-1 JRCSF strain. Also, Ghost R3/X4/R5 have the ability to express
GFP when infected with HIV-1, a feature used to quantify infection by flow cytometry. The results
of the infection of this cell line are presented in Figure 18.
To identify if there are different levels of apoptosis induced in this cell line by the different
isoforms, cells were stained with FVD and Annexin V 48 hours post-infection and analyzed by
flow cytometry. The results of this assay show a significantly higher level of apoptotic induction
by the R77Q isoform (10.88%) when compared to Vpr WT (3.42%) and R36W (4.00%), and no
significant difference was identified when compared to the Vpr null strain (Figure 21). Also, we
identified that Vpr null significantly induces more apoptosis than Vpr WT. These results differ
from our results using primary CD4+ CCR5+ T cells at a time point of 3 days post-infection, where
isoform R36W induced significantly more apoptosis than R77Q (Figure 17-A). Still, results of
induction of apoptosis in primary CD4+ CCR5+ T cells at day 5 are similar to the induction of
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apoptosis in Ghost R3/X4/R5 cells after 48 hours, where R77Q induced more apoptosis than Vpr
WT and R36W (Figure 17-B).
Regarding the cytopathic effect of the different strains, we found that cells infected with
Vpr null were significantly more viable (85.25% of cells) than Vpr WT and R36W (Figure 19).
The correlation between infected and viable cells by Vpr null shows that the capacity of this strain
to infect cells is not sufficient to induce cell death per se, but it is possible that because of the lack
of Vpr, Vpr null does not have the capacity to damage the cell enough to induce loss of cell
membrane (necrosis). Interestingly, no statistically significant difference was identified when Vpr
null was compared to R77Q, which had 67.33% viable cells after infection (Table 8, T-Test Healthy
cells). The similarity between Vpr null and R77Q indicates that the last also lacks the capacity to

induce an important amount of necrosis in infected cells.
Conversely, both Vpr WT and R36W significantly induced more cell death by necrosis
(61.89% and 69.87% respectively) than Vpr null (5.09%) (Figure 20). Notably R77Q had
significantly fewer necrotic cells (20.38%) than R36W, and fewer necrotic cells (p=0.08) than Vpr
WT (Table 8, T-Test Necrotic cells). Taking into account the percentage of viable and necrotic cells
after infection with R77Q, it appears that this isoform not only has the capacity to allow the cells
to stay healthy, but also prevents the cells from undergoing the process of necrosis. Our findings
for the isoform R77Q are similar to results presented by the group of Lum, et al, where T cell
infections using vesicular stomatitis virus G (VSV-G) pseudotyped HIV-1 Vpr R77Q resulted in
less necrotic T cells than infections using HIV-1 Vpr WT [161].
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Moreover, comparison between Vpr null and R77Q showed no significant differences in
the proportion of identified necrotic cells. Still, R77Q presented 20.38% necrotic cells, which
represents about four times the proportion of necrotic cells induced when infected by Vpr null
(5.09%) (Figure 20). Furthermore, when these two strains are compared to the uninfected control,
they did not present significant differences in the induction of necrosis (See Table 8, T-Test
Necrotic cells), implying that HIV-1 harboring mutation R77Q may not play an important role in

the depletion of cells in HIV-1 infected patients. These results support the hypothesis of the
association of HIV-1 Vpr R77Q mutation with the delayed progression of HIV-1, that groups
including Mologni, et al, and Lum, et al, have previously hypothesized [161, 162].
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CONCLUSION
In HIV-infected patients, cells dying by necrosis could be responsible for triggering a
systemic chronic immune activation, which process has been considered pivotal in the depletion
of CD4+ T cells and by consequence the progression to AIDS [169, 170]. In this study, we
identified that the Vpr isoform R36W significantly induced more necrosis than the isoform R77Q
in Ghost R3/X4/R5 cells (Figure 20). These results were not unexpected, and based on systemic
chronic immune activation hypothesis, they support the correlation of the isoform R36W to the
phenotype of RP AIDS patients [163]. On the other hand, we identified that Vpr isoform R77Q
not only induced less necrotic cells than R36W but allowed significantly more viable cells than
R36W (Figure 19). It appears that the presence of mutation R77Q diminishes the cytotoxic
capacity of Vpr on Ghost R3/X4/R5 cells, which idea supports the association of the isoform R77Q
to phenotype of LTNP AIDS patients [159].
Furthermore, we identified that isoform R77Q significantly induced more apoptosis on
Ghost R3/X4/R5 cells than R36W (Figure 21). Identification of apoptosis was an important
parameter to measure after infection, because it has been shown that cells undergoing apoptosis
do not trigger strong systemic inflammation [171]. Higher induction of apoptosis by R77Q could
be one of reasons for the delay of the chronic activation of the immune system that leads to AIDS.
Based on the correlation of the higher percentage of viable cells, lower induction of necrosis, and
more induction of apoptosis presented by R77Q when compared to R36W in Ghost R3/X4/R5
cells, we recognized that the R77Q mutation is a strong contributor to the delay of progression to
AIDS in LTNP patients.
Ghost R3/X4/R5 are osteoclasts modified to selectively express the coreceptor CCR5,
which confers on them the capacity to be infected by R5 tropic viruses like JRCSF. The results of
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this study could be reinforced if comparable results could be obtained using a R5 tropic permissive
T cell line, or isolated primary CD4+ CCR5+ T cells. Fortunately, there is one T cell line available
that is permissive to R5 tropic viruses, which is denominated Sup-T1 CCR5+ Cells (H6), and was
developed by the group of Joshi, et al [172].
Studies in vitro have been the base of understanding many of the processes that happen
during the course of infection with HIV-1. Despite their usefulness so far, it would be ideal to
utilize an in vivo model permissive to infection with HIV-1. One feasible model for this would be
humanized mice with a transplanted human immune system. Comparing the cytopathic effects and
induction of apoptosis between R77Q and R36W in an in vivo model like this would be a
determinant way to further understand their participation in the progression of HIV-1 to AIDS and
their correlation to LTNP and RP patients.
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PROTOCOLS
Protocol 1 - Transfection Of Mammalian Cells
(Calcium Chloride Method)
Day 1 – Cell seeding:
1. Plate HEK cells in a T-75 flask at 1 x 105 cells/ml the day before transfection using
DMEM medium containing 10% FBS. About 60% confluency is expected.
Day 2 – Cell transfection:
2. Change medium on cells 3 hr before beginning transfection.
3. Mix plasmid DNA with water in a 50 ml clear plastic tube and mix by gently vortexing
on a low setting (or flick) (See Table A for volumes of reagents).
4. Add 2 M calcium chloride to the DNA/water mixture and mix by gently vortexing on a
low setting (See Table A for volumes)
5. In another tube, pipet the appropriate volume of 2x HBS.
6. While gently vortexing the tube containing the 2x HBS, add the DNA/water/CaCl2
mixture dropwise. Incubate tube at room temperature for 30 min.
a. The mixture may appear slightly opaque after 30 min because of the formation of
the DNA/calcium phosphate precipitate (Clear plastic tubes are used to see more
easily the precipitate)
7. Gently vortex the mixture, then add dropwise directly to the medium on the cells. Gently
swirl the plate of cells while adding the mixture and incubate cells.
8. At 9 hrs post-transfection, change the medium on the cells.

67

Day 4 – Virus harvest:
9. At 36 hrs post-transfection, add 25%-50% volume of media.
10. At 48 hrs post-transfection, transfer the medium from the cells to a 50 ml centrifuge tube
and centrifuge 5 min at 1500 rpm room temperature.
11. Divide supernatants into 100 - 200 µL aliquots in cryovials (1.5 ml sterile Eppendorf
tubes).
12. Transfer the tubes to -80°C.

Table A. Appropriate Reagent Volumes for Calcium Chloride Transfection
6-well plate

60-mm dish

100-mm dish
T-75 Flask

HIV cDNA

2.5 µg

6-12 µg

10-20 µg

2 M CaCl2

10.34 µl

37 µl

62 µl

To 83.4 µl

To 300 µl

To 500 µl

2x HBS, pH7.05

83.4 µl

300 µl

500 µl

Total

166.8 µl

600 µl

1000 µl

Reagent

Nuclease-free water
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Protocol 2 - Fixable Viability Dye And Annexin V Staining
(For Flow Cytometry Analysis)
1. Pellet cells 1500 rpm for 5 min and discard supernatant.
2. Wash with 1 mL of serum free PBS, centrifuge at 1500 rpm for 5 min, discard supernatant.
3. Resuspend in 1 mL of serum free PBS.
4. Stain with 1µL/1-10x106 of Fixable Viability Dye (FVD), mix immediately.
5. Incubate 30 min at 4 oC protected from light, centrifuge at 1500 rpm for 5 min, discard
supernatant.
6. Add 1.75 µL of 85 mM CaCl2 to residual PBS (~100 µL), mix well and incubate for 10 min.
7. Stain with 5 µL of Annexin V, mix immediately.
8. Incubate for 15 min at 25 oC. Centrifuge 1500 rpm for 5 min, discard supernatant.
9. Resuspend in 100 µL of FACS buffer and add 1.75uL 85 mM CaCl2., Centrifuge at 1500
rpm for 5 min, discard supernatant.
10. Resuspend in 200 µL 1% PFA for 30 mins if cells are infected with HIV (10 min if not).
Centrifuge cells at 1500 rpm for 5 min, discard supernatant.
11. Resuspend in 150 - 200 µL of PBS, transfer to FACS tubes and analyze by flow cytometry.
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Protocol 3 - Staining For Viral Protein 24 (P24)
(For Flow Cytometry Analysis)
1. Pellet the cells 1500 rpm for 5 min and discard supernatant.
2. Wash, add in 1 mL of serum free PBS, centrifuge at 1500 rpm for 3 min, discard
supernatant (2X).
3. Resuspend in pellet in 100 µL of FACS staining buffer.
4. Add 3 µL Fc-block and incubate for 15 mins at 4 °C.
5. Dissociate pellet in remaining volume, usually about 100 µL (mix well).
6. Fix with 100 μL of solution A, mix well and incubate for 30 min at room temperature.
7. Add 1 ml of FACS buffer, mix and centrifuge at 1500 rpm for 3 min, discard supernatant.
8. Resuspend in 100 μL Solution B.
9. Add 0.5 μL of anti-p24 antibody and incubate for 15 mins at room temp.
10. Wash. Add 1 ml of FACS buffer, mix and centrifuge at 1500 rpm for 3 min, discard
supernatant (2X).
11. Resuspend cells in 150 – 200 µl of PBS or FACS buffer and analyze by flow cytometry.

70

GLOSSARY
Acute: short term, intense symptomatology, or pathology, as distinct from chronic. Many diseases
have an acute phase (like HIV seroconversion disease) and a chronic phase.
Antibody: is a large Y-shaped protein (also known as an immunoglobulin) produce by cells the
immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses.
The antibody recognizes a unique molecule of the pathogen, called an antigen.
Antigen: a toxin or other foreign substance which induces an immune response in the body,
especially the production of antibodies.
Apoptosis: the death of cells which occurs as a normal and controlled part of an organism's growth
or development.
Cytopathic effect (cytopathogenic effect): in virology, any change in the structure, morphology,
or physiology of a host cell that is caused by viral invasion. Common examples of CPEs include
rounding of the infected cell, fusion with adjacent cells to form syncytia, and the appearance of
nuclear or cytoplasmic inclusion bodies. These changes may or may not cause lysis and cell death.
Cytokine: any of a number of substances, such as interferon, interleukin, and growth factors,
which are secreted by certain cells of the immune system and have an effect on other cells.
Disease: a disorder of structure or function in a human, animal, or plant, especially one that
produces specific signs or symptoms or that affects a specific location and is not simply a direct
result of physical injury.
Emergent virus: Any virus that has recently adapted and emerged as a novel causative disease
agent. Emergent viruses are often the result of transmission between different species or a rapid
increase in the incidence or severity of the associated disease within a host population.
Epidemic: a widespread occurrence of an infectious disease in a community at a particular time.
Epidemiology: the branch of medicine which deals with the incidence, distribution, and possible
control of diseases and other factors relating to health.
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Erythrocyte: a red blood cell that (in humans) is typically a biconcave disc without a nucleus.
Erythrocytes contain hemoglobin, which imparts the red color to blood.
Immunodeficiency: failure of the immune system to protect the body adequately from infection,
due to the absence or insufficiency of some component process or substance.
Isoform: any of two or more functionally similar proteins that have a similar but not identical
amino acid sequence and are either encoded by different genes or by RNA transcripts from the
same gene.
Latency: in virology, 1.- the ability of a pathogenic virus to lie dormant or latent within a cell for
a period of time before reactivating and producing new, independent virions. 2.- The phase in the
life cycle of certain viruses in which, after initial infection, proliferation of virus particles ceases
while the viral genome remains silently assimilated into the host cell's genome, sometimes
indefinitely. The latent period ends when the virus reactivates and begins producing large amounts
of viral progeny without the host cell being infected by additional external virions. Latency is a
defining element of the lysogenic form of viral replication.
Lymphopenia (lymphocytopenia): a decrease in the number of lymphocytes in the blood, which
may occur in a wide variety of diseases.
Multiplicity of infection (MOI): the ratio of the number of infectious agents (e.g. individual viral
particles) to the number of infection targets (e.g. cells of a particular host) within a defined space.
Necrosis: death of cells in an organ or tissue due to disease, injury, or failure of the blood supply,
which result in the unregulated digestion of cell components.
Pandemic (of a disease): prevalent over a whole country or the world.
Pathogen: a bacterium, virus, or other microorganism that can cause disease.
Pathogenicity: 1. The quality or state of being pathogenic, the potential ability to produce disease.
2. The capacity of a microbe to cause damage in a host.
Percutaneous: made, done, or effected through the skin.
Phylogenetics: relating to the evolutionary development and diversification of a species or group
of organisms, or of a particular feature of an organism.
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Provirus: the genetic material of a virus as incorporated into, and able to replicate with, the
genome of a host cell.
Serology: the scientific study or diagnostic examination of blood serum, especially with regard to
the response of the immune system to pathogens or introduced substances.
Seropositive: giving a positive result in a test of blood serum, e.g. for the presence of a virus or
an antibody.
Vaccine: a substance used to stimulate the production of antibodies and provide immunity against
one or several diseases, prepared from the causative agent of a disease, its products, or a synthetic
substitute, treated to act as an antigen without inducing the disease.
Viral load: a numerical expression of the quantity of virus in a given volume, typically expressed
as the number of individual viral particles per unit volume but also by quantifying other factors
that are closely related to or influenced by viral concentration. Viral load often correlates with the
severity of an active viral infection.
Virion (viral particle): a singular, stable particle that is the independent form in which a virus
exists while not inside an infected cell or in the process of infecting a cell. Virions are the products
of a completed viral replication cycle; upon release from the infected cell, they are fully capable
of infecting other cells of the same type.
Virulence: the capacity of a pathogen to cause disease, defined broadly in terms of the severity of
symptoms experienced by an infected host. Other factors being equal, a viral strain which causes
severe symptoms in a susceptible individual may be considered highly virulent, while a different
strain which produces less severe or no symptoms in the same individual may be considered
relatively less virulent.
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APPENDIX
Table 10. Statistical analysis of Ghost R3/X4/R5 apoptotic cells (appendix).
% APOPTOTIC CELLS
1
UI
WT
R36W
R77Q
NULL

11.86
23.19
20.71
36.04
21.20

2

3

Avg

SD

SE

13.81
28.79
14.41
22.29
37.70

13.73
16.01
10.01
19.29
3.52

13.13
22.66
15.04
25.87
20.81

1.10
6.41
5.38
8.93
17.09

0.64
3.70
3.11
5.16
9.88

T-TEST APOPTOTIC CELLS
R77Q 0.079
0.312
0.021
0.335

UI
WT 0.064 UI
R36W 0.328 UI
Null 0.2593 UI
WT
0.082 R36W
0.294 Null
R36W
0.396 Null
Null

Figure 22. Apoptosis in Ghost R3/X4/R5 cells. R77Q induced significantly more apoptosis than R36W at
a time point of 48 hrs. post-infection. No significant differences were identified between other compared
strains.
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